Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer

A compound of Formula (I):

• wherein:
• X is selected from the group consisting of:
• S, NRN and O;
• wherein RN is selected from the group consisting of:
• H, C1-4 alkyl, C1-4 haloalkyl and C3-6 cycloalkyl, wherein the C1-4 alkyl, C1-4 haloalkyl and C3-6 cycloalkyl groups are themselves optionally substituted with a substituent selected from the group consisting of:
• RA1, halo, —ORA1, ═O, —NRA1RB1, —SRA1, —CN, —NO2, —NRA1C(O)RB1, —C(O)NRA1RB1, —NRA1C(O)ORB1, —OC(O)NRA1RB1, —NRA1C(O)NRA1RB1, —NRA1SO2RB1, —SO2NRA1RB1, —SO2RA1, —C(O)RA1, —C(O)ORA1 and C3-6 cycloalkyl;
• Y is selected from the group consisting of:
• N and CR;
• wherein R is selected from the group consisting of:
• H, halo, C1-4 alkyl, C1-4 haloalkyl, —ORA1, —NRA1RB1, —SRA1, —CN, —NO2, —NRA1C(O)RB1, —C(O)NRA1RB1, —NRA1C(O)ORB1, —OC(O)NRA1RB1, —NRA1C(O)NRA1RB1, —NRA1SO2RB1, —SO2NRA1RB1, —SO2RA1, —C(O)RA1, —C(O)ORA1 and C3-6 cycloalkyl, wherein the C1-4 alkyl, C1-4 haloalkyl and C3-6 cycloalkyl groups are themselves optionally substituted with a substituent selected from the group consisting of:
• RA1, halo, —ORA1, ═O, —NRA1RB1, —SRA1, CN, —NO2, —NRA1C(O)RB1, —C(O)NRA1RB1, —NRA1C(O)ORB1, —OC(O)NRA1RB1, —NRA1C(O)NRA1RB1, —NRA1SO2RB1, —SO2NRA1RB1, —SO2RA1, —C(O)RA1, —C(O)ORA1 and C3-6 cycloalkyl;
• Z is carbon and is bonded to the
• residue and W is selected from the group consisting of:
• N and CR;
• wherein R is selected from the group consisting of:
• H, halo, —ORA1, —NRA1RB1, —SRA1, —CN, —NO2, —NRA1C(O)RB1, —C(O)NRA1RB1, —NRA1C(O)ORB1, —OC(O)NRA1RB1, —NRA1C(O)NRA1RB1, —NRA1SO2RB1, —SO2NRA1RB1, —SO2RA1, —C(O)RA1, —C(O)ORA1 and C3-6 cycloalkyl, wherein the C3-6 cycloalkyl groups are themselves optionally substituted with a substituent selected from the group consisting of:
• RA1, halo, —ORA1, ═O, —NRA1RB1, —SRA1, CN, —NO2, —NRA1C(O)RB1, —C(O)NRA1RB1, —NRA1C(O)ORB1, —OC(O)NRA1RB1, —NRA1C(O)NRA1RB1, —NRA1SO2RB1, —SO2NRA1RB1, —SO2RA1, —C(O)RA1, —C(O)ORA1 and C3-6 cycloalkyl;
• x is 1 or 2;
• n is 0, 1, 2, 3, 4, 5 or 6;
• R1 and R2 are independently selected at each occurrence from:
• H, halo, C1-4 alkyl, C1-4 haloalkyl, —ORA1, —NRA1RB1, —CN, —NO2, —NRA1C(O)RB1, —C(O)NRA1RB1, —NRA1SO2RB1, —SO2NRA1RB1, —SO2RA1, —C(O)RA1, —C(O)ORA1 and C3-6 cycloalkyl, or together R1 and R2 are ═O, wherein the C1-4 alkyl, C1-4 haloalkyl and C3-6 cycloalkyl groups are themselves optionally substituted with RA1, halo, —ORA1, ═O, —NRA1RB1, —SRA1, —CN, —NO2, —NRA1C(O)RB1, —C(O)NRA1RB1, —NRA1C(O)ORB1, —OC(O)NRA1RB1, —NRA1C(O)NRA1RB1, —NRA1SO2RB1, —SO2NRA1RB1, —SO2RA1, —C(O)RA1, —C(O)ORA1 and C3-6 cycloalkyl;
• when n is 0, R3 is optionally substituted 3- to 15-membered ring system, including 0, 1, 2 or 3 heteroatoms selected from N, O or S, wherein the ring system is connected to the remainder of the compound of Formula (I) via a carbon atom, and when n is 1, 2, 3, 4, 5 or 6 R3 is selected from the group consisting of optionally substituted 3- to 15-membered ring system, including 0, 1, 2 or 3 heteroatoms selected from N, O or S, halo, —ORA1, —NRA1RB1, —SRA1, —CN, —NO2, —NRA1C(O)RB1, —C(O)NRA1RB1, —NRA1C(O)ORB1, —OC(O)NRA1RB1, —NRA1C(O)NRA1RB1, —NRA1SO2RB1, —SO2NRA1RB1, —SO2RA1, —C(O)RA1 and —C(O)ORA1;
• and
• RA1 and RB1 are at each occurrence independently selected from the group consisting of:
• H, C1-4 alkyl, C1-4 haloalkyl and C1-4 alkyl substituted with a substituent selected from the group consisting of:
• —ORA5, —NRA5RB5, —CN, —NO2, —N3, —NRA5C(O)RB5, —C(O)NRA5RB5, —NRA5SO2RB5, —SO2NRA5RB5, —SO2RA5, —C(O)RA5, —C(O)ORA5 and C3-6 cycloalkyl, wherein RA5 and RB5 are each independently selected from the group consisting of H and C1-4 alkyl;
• wherein in the specific group —NRA1RB1, RA1 and RB1, together with the nitrogen atom to which they are bonded can form a 4- to 7-membered ring system;
• and wherein in the specific group —NRA5RB5, RA5 and RB5, together with the nitrogen atom to which they are bonded can form a 4- to 7-membered ring system;
• or a pharmaceutically acceptable salt thereof.